Transsphenoidal surgery is the first-line treatment for acromegaly. However, several factors
can modify surgical remission rates, such as the initial hormone levels, the size and …

Background Endocrine neoplasms are generally slow-growing tumors that can show
hormonal activity and give metastases. In most cases they are benign and clearly malignant …

Introduction Usually benign, pituitary tumors (PT) can be invasive and aggressive with a
propensity to progress and/or recur. Trouillas's clinicopathological classification attempts to …

Background The Ki-67 index is an indicator of proliferation and aggressive behavior in
pituitary adenomas (PAs). This study aims to develop and validate a predictive nomogram …

Acromegaly is a rare endocrine disorder, which despite the recent advances in diagnosis
and management, remains a significant burden in terms of morbidity and mortality for …

Cushing's disease (CD) is characterized by endogenous hypercortisolism that is associated
with increased mortality and morbidity. Due to high recurrence rates in CD, the …

Acromegaly is a disease mainly caused by pituitary neuroendocrine tumor (PitNET)
overproducing growth hormone. First-line medication for this condition is the use of …

Introduction Temozolomide (TMZ) is currently considered as a rational therapeutic option for
patients with progressively aggressive pituitary adenomas and carcinomas not responding …

Introduction Acromegaly is a chronic disease of increased growth hormone (GH) secretion
and elevated insulin-like growth factor-I (IGF-I) levels induced by a pituitary adenoma …

Modern problems of acromegaly treatment are associated with the heterogeneous
composition of somatotrophic tumors, differing in clinical course and sensitivity to the …